Teva USA settles with Pfizer on generic Celebrex

JERUSALEM — Teva Pharmaceutical on Thursday announced that its U.S. subsidiary has entered into a settlement with Pfizer related to Teva's generic version of Celebrex (celecoxib) 50-, 100-, 200- and 400-mg capsules in the United States.

Under the terms of the settlement, Teva may launch its generic versions in December, 2014, or earlier under certain circumstances. Teva has received tentative approval from the Food and Drug Administration for all strengths and believes that it is first-to-file on at least the 100-, 200- and 400-mg capsules. 

Sales of Celebrex were $2.2 billion in the U.S. according to IMS data as of December, 2013.